Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells

Xiao Wang, Xu Xuetao, Mengshuo Wu, Panpan Wu, Zhaojun Sheng, Wenfeng Liu, Yan-Yan Ma, Den-Gao Zhao, Kun Zhang, Dongli Li, Xi Zheng and Susan Goodin

ABSTRACT
Roburic acid (ROB) is a naturally occurred tetracyclic triterpenoid, and the anticancer activity of this compound has not been reported. Docetaxel (DOC) is the first-line chemotherapeutic agent for advanced stage prostate cancer but toxic side effects and drug resistance limit its clinical success. In this study, the potential synergistic anticancer effect and the underlying mechanisms of ROB in combination with DOC on prostate cancer were investigated. The results showed that ROB and DOC in combination synergistically inhibited the growth of prostate cancer cells. The combination also strongly induced apoptosis, and suppressed cell migration, invasion and sphere formation. Mechanistic study showed that the combined effects of ROB and DOC on prostate cancer cells were associated with inhibition of NF-κB activation, down regulation of Bcl-2 and up regulation of Bax. Knockdown of NF-κB by small interfering RNA (siRNA) significantly decreased the combined effect of ROB and DOC. Moreover, we found that esomeprazole (ESOM), a proton pump inhibitor (PPI), strongly enhanced the effectiveness of ROB and DOC on prostate cancer cells in acidic culture medium. Since acidic micro environment is known to impair the efficacy of current anticancer therapies, ESOM combined with ROB and DOC may be an effective approach for improving the treatment of prostate cancer patients.

GRAPHICAL ABSTRACT

1. Introduction
Prostate cancer is the most prevalent male urogenital malignancy and the second leading cause of cancer death in US men. Risk factors including advancing age, race, geographical distribution, diet and family history are contributing to the incidence of this disease. For the treatment options of prostate cancer, early stages of the disease can be managed with active surveillance, radical prostatectomy, or radiation therapy. Patients who are not suitable for surgical intervention can be treated with androgen deprivation. However, prostate cancer cells lose their hormone dependence and therapeutic responsiveness during disease progression. When the disease progresses to the hormone-refractory stage (also referred to as androgen-independent), chemotherapy is the only option left for these patients.

Docetaxel (DOC; Figure 1) is an anti-mitotic agent, which is able to restrain microtubule disassembly and prevent the formation of mitotic spindles. DOC chronically activates the spindle assembly checkpoint (SAC), which in turn leads to mitotic arrest and eventually induces cell death. DOC is the first-line chemotherapy for treatment of advanced stage prostate cancer. The combination of DOC with androgen deprivation therapy was also used in metastatic or high-risk localised hormone-sensitive prostate cancer. The survival of patients after DOC chemotherapy remains limited. Systemic side effects of DOC hamper the patient’s compliance and drug resistance invariably emerges, leading to...
disease relapse. Therefore, approaches to improve DOC-based chemotherapy in prostate cancer patients are urgently needed.

It is of highly clinical significance to identify agents that have synergistic effect when combined with DOC. Synergistic combinations may allow to decrease the dose of DOC without reducing its effectiveness. Lowering the dose of DOC will decrease its toxic side effects. Effective combinations may also overcome DOC resistance. Roburic acid (ROB; Figure 1) is a naturally occurred tetracyclic triterpenoid. ROB was originally isolated from oak galls, and later also found in Gentiana macrophylla Pall, etc.14–16. The bioactivity of ROB was rarely reported. A study conducted by Chen et al. demonstrated that ROB inhibited nitric oxide (NO) and interleukin (IL)-6 via targeting nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathway in murine macrophage RAW264.7 cells17. However, the anticancer activity of ROB has not been reported.

It is well known that the Warburg effect leads tumours to become acidic, and the acidic extracellular pH is a well recognised feature of tumour environment18. The tumour microenvironment acidification is a real phenotype that bursts the malignant behaviour of virtually all tumours, including prostate cancer19. Acidic tumour microenvironment increases tumour invasion, metastasis and chemotherapeutic drug resistance19. Interestingly, tissue acidification is common to type II diabetes as well20, suggesting that microenvironmental acidity is a common pathway of many human pathologies. Therefore, it is important to determine the activities of potential new anticancer compounds such as roburic acid in buffered pH and low pH conditions. Moreover, many laboratory-based and clinical studies have demonstrated that tumour acidity decreased the efficacy of chemotherapeutic agents, and antiacidic drugs such as proton pump inhibitors (PPIs) improved the effectiveness of anticancer therapies21–34. Combined potential new anticancer agents with PPIs is highly relevant for developing effective anticancer combination therapies.

In the present study, we investigated the inhibitory effects of ROB, DOC and ESOM alone or in combination on human prostate cancer cells in pH7.4 and pH6.5 culture conditions. The mechanisms associated with the effects of ROB in combination with DOC was determined. Results of the present study demonstrated for the first time that ROB combined with DOC had synergistic effect on inhibiting the growth of prostate cancer cells. The combination also induced apoptosis, suppressed cell migration, invasion and sphere formation. Mechanistic studies indicate that the effects of ROB and DOC were associated with inhibition of NF-κB activation, down regulation of Bcl-2 and up regulation of Bax. Furthermore, we found that ESOM strongly enhanced the efficacy of ROB and DOC on prostate cancer cells in acidic culture medium. The strong combined effect of ROB, DOC and ESOM warrants further in vivo studies using suitable animal models.

2. Materials and methods

2.1. Cell line and cell culture

Human prostate cancer cell lines (LNCaP, VCaP and PC-3) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were propagated in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% foetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 mg/ml), and L-glutamine (300 μg/ml) (All from Gibco, Grand Island, NY, USA). The acidic cell culture medium (pH 6.5) was obtained by the addition of 1 M HCl solution. The cells were grown at 37°C in a humidified atmosphere of 5% CO₂. ESOM, ROB and DOC were obtained from Sigma-Aldrich (St. Louis, MO, USA). The compounds were dissolved in DMSO to make stock solution, and the final concentration of DMSO in all experiments was 0.2%.

2.2. Cell viability assay

The cells were seeded at a density of 1.5 × 10⁴ cells/ml of medium in a 96-well plate (0.2 ml/well). The cells were incubated for 24 h before treatment with DOC and/or ROB for 72 h. Following treatment, 10 μL Cell Counting Kit-8 (CCK-8) (CK04-11, VitaScientific, Beltsville, MD, USA) was added into each well and the cells were incubated for 30 min. A microplate reader ChroMate™ (Awareness Technology, Palm City, FL, USA) was used to detect the optical density (OD) at a wavelength of 450 nm.

2.3. Apoptosis assay

Apoptosis was determined by morphological assessment in cells stained with propidium iodide (PI). After each experiment, cells were trypsinized and cytopsin slides were prepared. The cells were fixed with acetone/methanol (1:1) for 10 min at room temperature, followed by 10 min with propidium iodide staining (1 μg/ml in PBS), and finally analysed using the CELENA® fluorescence imaging system (Lagos Biosystem, Annandale, VA, USA).
2.4. Caspase-3 assay
Caspase-3 activation was measured using an EnzoLyte AMC Caspase-3 Assay Fluorometric kit (AnaSpec, Fremont, CA) following the manufacturer instructions. Briefly, 1 × 10^5 cells were plated in triplicate in a flat-bottomed 96-well plate. After drug treatment, caspase-3 substrate was added to each well. Plates were incubated for 30 min at room temperature. Fluorescence intensity was measured in a Tecan Infinite M200 plate reader (Tecan US Inc., Durham NC, USA). For the caspase-3 immunofluorescence staining, cytospin of PC-3 cells were fixed in acetone/methanol (1:1) for 10 min at room temperature. The cells were incubated with caspase-3 primary antibody (active form, #9661, Cell Signalling Tech, Danvers, MA, USA). After washing with PBS, the cells were incubated with FITC-conjugated secondary antibody. The caspase-3 immunofluorescence staining was examined using the CELENA® fluorescence imaging system (Lagos Biosystem, Annandale, VA, USA).

2.5. Sphere formation assay
PC-3 cells were seeded at a density of (1 × 10^5 cells/mL) in ultra-low attachment surface culture plate (Corning Co, NY, USA) and cultured in Keratinocyte SFM medium supplemented with EGF, insulin, selenium and transferrin (Gibco, Grand Island, NY, USA). The cells were treated with ROB and/or DOC. On day 12, the number of spheres were counted under an inverted microscope (Optiphot, Nikon, Tokyo, Japan).

2.6. Cell migration assay
PC-3 cells were seeded in 6-well culture plates at a density of 8 × 10^5 cells/ml and grown to confluency. Monolayers of confluent PC-3 cells were then wounded using a 200 μl pipette and washed with PBS. The cells were treated with ROB and/or DOC, and cell migration was monitored using an inverted microscope (Optiphot, Nikon, Tokyo, Japan), and images were obtained at 0 h and 24 h. The wounded areas were measured by ImageJ software and the relative wound closure was expressed as a ratio of the original scratch area.

2.7. Invasion assays
PC-3 cells (2 × 10^5 cells/well) were plated in serum-free RPMI medium in the top chamber with a membrane (24 well insert; pore size, 8 μm; Corning Inc.) coated in Matrigel (1 mg/ml; BD Biosciences, San Jose, CA, USA). RPMI medium containing 10% serum was used as a chemotactrant in the lower chamber. Following incubation for 24 h, a cotton swab was used to remove the non-migrated cells in the upper chamber and the filters were individually stained with 2% crystal violet. The migrated cells were individually stained with 2% crystal violet. The migrated cells were counted under an inverted microscope (Optiphot, Nikon, Tokyo, Japan).

2.8. NF-κB-dependent reporter gene expression assay
PC-3/N cells were treated with ROB and/or DOC for 24 h, and then the cells were harvested in 1× reporter lysis buffer (Promega, Madison, WI, USA). After centrifugation, 10 μl aliquots of the supernatants were mixed with 10 μl of luciferase substrate (Promega) and measured for the luciferase activity by using a Luminometer LuMate™ (Awareness Technology, Palm City, FL, USA). The luciferase activity was normalised against known protein concentrations and expressed as the percentage of luciferase activity in the control cells. The protein level was determined by Bio-Rad protein assay kits (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions.

2.9. Transfection with NF-κB p65 siRNA
NF-κB p65 small interfering RNA (siRNA) and scrambled negative control siRNA were from Cell Signalling Tech (Danvers, MA, USA). PC-3 cells were seeded in 6-well plates and incubated for 24 h to allow adherence of cells. SiRNA was transfected into the cells using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. The final concentration of siRNA was 100 nM. After 48 h, the cells were harvested for expression assay or treating with ROB and/or DOC.

2.10. Western blotting
After treatment, the cells were lysed and the proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocelulose membranes. After blocking non-specific binding sites with blocking buffer, the membranes were incubated overnight at 4 °C with primary antibodies (69565 for NF-κB p65, 15071 for Bcl-2, 5023 for Bax and 2808 for survivin; Cell Signalling Tech, Beverly, MA, USA). β-actin (sc-47778, Santa Cruz Biotechnology Inc., Dallas, TX, USA) was used as a loading control. Following the removal of the primary antibodies, the membranes were washed three times with TBS (PBS containing 0.05% Tween 20) buffer at room temperature and later incubated with fluorochrome-conjugated secondary antibody (925–3221, LiCor Biotechnology, Lincoln, NE, USA). The membrane was then washed with TBS three times. Final detection was done with an Odyssey infra-red imaging system (Li-Cor Biotechnology).

2.11. Measurement of intracellular pH change
The change in intracellular pH was as previously described. Briefly, cells grown on 35 mm dishes were treated with ESOM for 24 h and incubated with 1 μg/mL BCECF-AM solution for 30 min. Fluorescence staining was determined using the CELENA® fluorescence imaging system.

2.12. Statistical analyses
Statistical analyses were done by using the software InStat (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons of treatment outcome were analysed for statistical difference by ANOVA. Statistical significance was assumed at a value of p < 0.05. Analysis of synergy was performed using the CompuSyn software based on the isobologram principle. The combination index (CI) was used for data analysis of two-drug combinations. Index values of CI < 1, CI = 1 and CI > 1 indicate synergism, additive effect and antagonism, respectively.

3. Results and discussion
3.1. Effects of ROB on human prostate cancer cells and normal prostate epithelial cells
In initial studies, we determined the effects of ROB on cell growth and apoptosis in human prostate cancer LNCaP, VCaP and PC-3 cells. After treatment with ROB for 72 h, all three cell lines...
exhibited dose-dependent decreases in cell viability (Figure 2(A)). Treatment of the cells with ROB resulted in apoptosis in a dose-dependent manner (Figure 2(B)). ROB had similar effects on cell viability and apoptosis among the three prostate cancer cell lines tested. We also determined the effect of ROB on cell viability of normal prostate epithelial RWPE-1 cells. As shown in Figure 3(A), ROB at low doses did not affect the cell viability while at doses of 20 and 50 \( \mu \text{M} \), significant decreases in cell viability were seen in the cells (Figure 3(A)).

### 3.2. Inhibitory effect of ROB and DOC in combination on human prostate cancer cells

To explore the potential synergistic effect of ROB and DOC, we first determined the inhibitory effect of DOC on prostate cancer cells. As shown in Figure 3(B), treatment LNCaP, VCaP and PC-3 cells with DOC dose-dependently decreased the cell viability. Since DOC is clinically used in late stage prostate cancer patients, the androgen-independent PC-3 cells were used in subsequent experiments to determine the combined effect of ROB and DOC. PC-3 cells were treated with ROB at non-toxic doses in combination with low doses of DOC, and the potential synergistic effect of the combinations was determined using the CompuSyn software. As shown in Figures 3(C,D), combinations of ROB and DOC at different dose ratios had synergistic effect. The CI for each combination of ROB and DOC is shown in Figure 3(E). ROB (10 \( \mu \text{M} \)) combined with DOC (1 nM) had the lowest CI (0.46) among the combinations indicating a strong synergistic effect.

### 3.3. Effect of ROB and DOC in combination on apoptosis of PC-3 cells

The effects of ROB and DOC alone or in combination on apoptosis of PC-3 cells were assessed by propidium iodide staining and caspase-3 assays. It was observed in PI staining assay that DOC and ROB alone had small to moderate effects on stimulating apoptosis, while the combination of these two agents strongly induced apoptosis. Representative micrographs of PI staining in the untreated, ROB-treated, DOC-treated and combination-treated cells are shown (Figure 4(A)). As shown in Figure 4(B), cells treated with the combination of ROB and DOC had significantly more apoptotic cells than that in cells treated with ROB or DOC alone (\( p < 0.001 \)). The effect of ROB and DOC on apoptosis was confirmed by the caspase-3 assay. As shown in Figure 4(C), caspase-3 activity was strongly increased in the cells treated with the combination of ROB and DOC (\( p < 0.001 \) as compared to DOC- or ROB-treated cells). Figure 4(D) shows representative micrographs of caspase-3 (active form) immunofluorescence staining in untreated, DOC-treated, ROB-treated and DOC + ROB-treated cells.

### 3.4. Inhibitory effect of ROB and DOC on PC-3 cell migration and invasion

We next determined the effects of DOC and ROB on migration and invasion of PC-3 cells. Scratch wound healing assay was used to examine the migration of PC-3 cells. Following incubation with DOC and ROB for 24 h, the migration of PC-3 cells to the denuded area was inhibited (Figure 5(A)). The combination of ROB and DOC had stronger effect than either agent alone on suppressing the migration of PC-3 cells. Statistical analysis using ANOVA showed that the migration rate in the combination-treated group was significantly lower than that in ROB- or DOC-treated group (\( p < 0.001 \)). Results of the invasion assay revealed that ROB and DOC inhibited the invasion of PC-3 cells through the Matrigel-coated filter pores (Figure 5(B)). The combination of DOC and ROB strongly inhibited cell invasion. Statistical analysis using ANOVA showed that the migration rate in the combination-treated group was significantly lower than that in ROB- or DOC-treated group (\( p < 0.001 \)). Taken together, the results described above revealed that DOC and ROB in combination strongly suppressed cellular migration and invasion of PC-3 cells.
3.5. Suppression of sphere formation in prostate cancer cells by ROB and DOC

Cancer stem cells (CSCs) are a small sub-population of tumour cells that retain the ability to renew and differentiate. CSCs have self-renewal capacity and are considered to play important roles in cancer chemoresistance and relapse. It is well characterised that CSCs can form three dimensional spheres in vitro in serum-free suspension cultures. Therefore, we investigated the effects of ROB and DOC on PC-3 cell sphere formation in serum free medium. When culturing in ultralow attachment plate with serum-free medium, a small fraction of the PC-3 cells formed spheres. Treatment with DOC had little effect on sphere forming efficiency (SFE) and ROB alone had a moderate effect on decreasing SFE (Figure 6(A)). The combination of ROB and DOC strongly decreased the SFE in PC-3 cells (**p < 0.001 as compared to ROB- or DOC-treated group). Treatment with ROB combined with DOC also decreased the size of the spheres (Figure 6(B)).

We also investigated if ROB and DOC induced apoptosis in PC-3 sphere-forming cells. The spheres formed in serum-free culture medium were dissociated by Accutase to make single cell suspension, and the cells were treated with DOC or ROB alone or in combination. As shown in Figure 6(C), treatment with DOC or ROB alone had small to moderate effect on increasing apoptosis while the combination had a significantly stronger effect on apoptosis than either agent used alone (**p < 0.001). Result of the caspase-3 activity assay and immunofluorescence staining confirmed that DOC combined with ROB had potent effect on increasing apoptosis in sphere-forming cells (Figure 6(D)). Representative micrographs of caspase-3 (active form) immunofluorescence staining in the cells treated with DOC and ROB alone or in combination are shown in Figure 6(E). Since the sphere formation assay is a classic method for the analysis of self-renewal ability, our result indicates that the combination of ROB and DOC suppresses the self-renewal of prostate CSCs. Moreover, the strong apoptotic effect of the ROB and DOC combination on sphere-forming cells suggests that DOC combined with suitable agents may provide an effective approach for eliminating prostate CSCs.

3.6. Effects of ROB and DOC on NF-κB, Bcl-2, Bax and survivin in PC-3 cells

To explore the mechanisms underlying the inhibitory effect of ROB and DOC on PC-3 cells, we investigated the effect of ROB
and DOC on NF-κB activation in PC-3 cells. NF-κB is constitutively activated in human prostate cancer\textsuperscript{42}, and previous studies have demonstrated that inhibition of NF-κB enhanced the efficacy of DOC in prostate cancer cells\textsuperscript{43,44}. In our study, we first determined the cellular localisation of NF-κB by immunofluorescence. As shown in Figure 7(A), most of the untreated PC-3 cells showed nuclear staining of NF-κB. Cells treated with DOC also showed nuclear staining of NF-κB. ROB decreased nuclear staining in some cells while the combination of ROB and DOC strongly decreased the nuclear staining of NF-κB (Figure 7(A)). This result indicated that ROB + DOC strongly inhibited the nuclear translocation of NF-κB which is a critical step in the process of its activation\textsuperscript{45}. To further evaluate if ROB and DOC suppressed the function of NF-κB, we used the luciferase reporter assay to determine the transcriptional activity of NF-κB. As shown in Figure 7(B), treatment of the cells with DOC had little effect on NF-κB transcriptional activity. ROB alone caused modest decrease in the transcriptional activity of NF-κB. Treatment with the combination of ROB and DOC strongly decreased the NF-κB transcriptional activity (Figure 7(B)). Statistical analysis using ANOVA demonstrated that NF-κB transcriptional activity was significantly lower in the combination-treated cells than in ROB- (\(p < 0.01\)) or DOC-treated cells (\(p < 0.001\)).

To further explore if the combined effect of ROB and DOC is mediated through NF-κB inhibition, we determined the influence of knocking down NF-κB through siRNA on the inhibitory effect of
ROB and DOC. As shown in Figure 7(C), the level of NF-κB p65 protein was decreased in the cells transfected with NF-κBp65 siRNA. Knocking down NF-κB through siRNA significantly reduced the combined effect of ROB and DOC on decreasing the viability of PC-3 cells (p < 0.01, analysed by ANOVA). This result suggests that the inhibitory effect of ROB and DOC in combination is at least partially mediated through inhibition of NF-κB.

Since the combination of DOC and ROB induced apoptosis, we evaluated the influence of the combination treatment on the levels of Bcl-2 and Bax. As shown in Figure 7(E), treatment of PC-3 cells with the combination of DOC and ROB strongly decreased the level of Bcl-2 and increased the level of Bax. Proteins of the Bcl-2 family play a fundamental role in regulation of apoptosis. Among members of the Bcl-2 family, Bcl-2 is a potent suppressor of apoptosis, whereas Bax is a pro-apoptotic protein. Higher levels of Bax relative to Bcl-2 may increase the susceptibility of cancer cells to apoptosis. The result of our study suggests that ROB combined with DOC induced apoptosis in PC-3 cells through upregulation of Bax and downregulation of Bcl-2. We also determined the effect of ROB and DOC on the level of survivin, a member of the inhibitor of apoptosis (IAP) family which plays an important role in apoptosis regulation. However, no combined effect on decreasing the level of survivin was observed in cells treated with ROB and DOC in combination.

3.7. Effects of ROB and DOC on PC-3 cells in pH 7.4 and pH 6.5 culture media

PC-3 cells were cultured in pH7.0 medium and then in pH6.5 medium over a 3-week period to adapt the acidic culture condition. After that, the cells were treated with ROB and DOC alone or in combination in pH6.5 medium. For comparison, original
PC-3 cells were cultured in normal medium (pH7.4) and treated with ROB and/or DOC. As shown in Figure 8(A), DOC induced a dose-dependent decrease in cell viability, and it was clear evident that PC-3 cells cultured in pH6.5 medium were more resistant to DOC than the cells cultured in pH7.4 medium (Figure 8(A)). This result is in line with a recent report showing that acidic pH-tolerant PC-3 cells were relatively resistant to DOC as compared to their parental cells (A). As shown in Figure 8(B), PC-3 cells cultured in acidic medium (pH6.5) were less sensitive to ROB as compared to PC-3 cells cultured in pH7.4
medium. However, the differences were not statistically significant (Figure 8(B)). As shown in Figure 8(C), PC-3 cells cultured in acidic medium (pH6.5) were also less sensitive to the combination of DOC and ROB. These results indicate that the acidic extracellular microenvironment is an important factor affecting the efficacy of anticancer agents. Potential new anticancer compounds should be tested for their effect on cancer cells cultured in acidic pH medium.

PPIs are among the most prescribed medications worldwide for peptic ulcers and gastroesophageal reflux. It has been reported that PPIs enhanced the effectiveness of anticancer agents. Therefore, we investigated the effect of ESOM, a pharmacological PPI, on the activity of ROB and DOC in PC-3 cells. As shown in Figure 8(D), ESOM had a more potent inhibitory effect on PC-3 cells cultured in pH6.5 medium than that in pH7.4 medium. This finding is consistent with the result of an earlier study using melanoma cells. Moreover, we found that ESOM enhanced the effects of ROB + DOC on PC-3 cells, and the effect of ESOM on the combination of ROB and DOC was significantly stronger in the cells in pH6.5 medium than that in pH7.4 medium (Figure 8(E)). These results indicate that PPIs may represent an effective approach for enhancing the efficacy of DOC and ROB in prostate cancer cells.

It is known that cancer cells have a characteristic microenvironment with reversed pH gradient resulted from an acidic extracellular pH and an alkaline intracellular pH. Recent studies have shown that PPIs decreased intracellular pH in cancer cells and enhanced the efficacy of paclitaxel (B, C). In the present study, we used the BCECF-AM probe to measure changes in cytosolic pH in PC-3 cells. As shown in Figure 8(F), treatment of PC-3 cells with ESOM reduced the fluorescence intensity indicating a decrease in intracellular pH in the cells. The combination of ESOM together with DOC and ROB also had a decreased fluorescence intensity. It is possible that the combined effect of ESOM with DOC and ROB on PC-3 cells was mediated at least in part by decreasing the cytosolic pH in the cells.

4. Conclusion

ROB and DOC in combination synergistically inhibited the growth of prostate cancer cells. The combination also strongly induced...
apoptosis, and suppressed cell migration, invasion and sphere formation. The strong combined effects of ROB and DOC on prostate cancer cells were associated with suppression of NF-κB, downregulation of Bcl-2 and upregulation of Bax. Moreover, the pharmacological PPI ESOM strongly enhanced the inhibitory effect of ROB and DOC on PC-3 cells. Results of our study indicate that combination of ROB and DOC together with PPIs may represent an effective approach for improving the treatment of prostate cancer patients.

Disclosure statement
No potential conflict of interest was reported by the author(s).
**Funding**

The present study was supported by grants from the Department of Education of Guangdong Province [2017KZDXM084, 2017KSYS010, 2019KZDZX003, and 2019KZDXM035], the Jiangmen Program for Innovative Research Team [No: 2017TD02], and the Department of Science and Technology of Jiangmen [No: 201635010170008351, 201810100330005446]. Dr. Xi Zheng is the Unilever Chair in Nutrition and Disease Prevention Research at Rutgers University.

**ORCID**

Dongli Li [http://orcid.org/0000-0001-9955-2304](http://orcid.org/0000-0001-9955-2304)

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
3. Perdana NR, Mochtar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones 2016;48:228–38.
4. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532–42.
5. Devlin HL, Mudrj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009;274:177–86.
6. Schroder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:i1129–37.
7. Ingrosso G, Detti B, Scartoni D, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol 2018;45:303–15.
8. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011;29:3686–94.
9. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579–85.
10. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65.
11. Tannock LF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
12. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
13. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–7.
14. Wu LH, Annie Bligh SW, Leon CJ, et al. Chemotaxonomically significant roburic acid from section cruciata of gentiana. Biochem Syst Ecol 2012;43:152–5.
15. Verhoff M, Seitz S, Paul M, et al. Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1. J Nat Prod 2014;77:1445–51.
16. Hou SB, Wang X, Huang R, et al. Seven new chemical constituents from the roots of Gentiana macrophylla pall. Fitoterapia 2020;141:104476.
17. Chen Y, Ji N, Pan S, et al. Roburic acid suppresses NO and IL-6 production via targeting NF-κB and MAPK pathway in RAW264.7 cells. Inflammation 2017;40:1959–66.
18. Schwartz L, Seyfried T, Alfarouk KO, et al. Out of Warburg effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Semin Cancer Biol 2017;43:134–8.
19. Pillai SR, Damaghi M, Marunaka Y, et al. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev 2019;38:205–22.
20. Gillies RJ, Pilot C, Marunaka Y, Fais S. Targeting acidity in cancer and diabetes. BBA Rev Cancer 2019;1871:273–80.
21. Spugnini EP, Fais S. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opin Ther Pat 2020;30:15–25.
22. De Milito A, Canese R, Marino ML, et al. pH-dependent anti-tumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010;127:207–19.
23. Logozzi M, Mizzoni D, Angelini DF, et al. Microenvironmental pH and exosome levels interplay in human cancer cell lines of different histotypes. Cancers 2018;10:370.
24. Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:85.
25. Falcone R, Roberto M, D’Antonio C, et al. High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: a case series and the state of art. Dig Liver Dis 2016;48:1503–5.
26. Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med 2013;11:268.
27. Spugnini EP, Oldani A, Buglioni S, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221.
28. Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225.
29. Papagerakis S, Bellile E, Peterson LA, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res 2014;7:1258–69.
30. Chen CH, Lee CZ, Lin YC, et al. Negative association of proton pump inhibitors with subsequent development of breast cancer: a nationwide population-based study. J Clin Pharmacol 2019;59:350–5.
31. Ding DC, Sung FC, Chen W, et al. Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: a population-based cohort study. Breast J 2020;26:474–8.
32. Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res 2014;7:1258–69.
33. Chen CH, Lee CZ, Lin YC, et al. Negative association of proton pump inhibitors with subsequent development of breast cancer: a nationwide population-based study. J Clin Pharmacol 2019;59:350–5.
34. Ding DC, Sung FC, Chen W, et al. Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: a population-based cohort study. Breast J 2020;26:474–8.
35. Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res 2014;7:1258–69.
36. Chen CH, Lee CZ, Lin YC, et al. Negative association of proton pump inhibitors with subsequent development of breast cancer: a nationwide population-based study. J Clin Pharmacol 2019;59:350–5.
34. Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015;356:697–703.
35. Huang H, Chen X, Li D, et al. Combination of z-tomatine and curcumin inhibits growth and induces apoptosis in human prostate cancer cells. PLOS One 2015;10:e0144293.
36. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008;26:2862–70.
37. Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011;112:255–81.
38. Portillo-Lara R, Alvarez MM. Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator ΔNp63α. PLOS One 2015;10:e0130118.
39. Gao W, Wu D, Wang Y, et al. Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. Stem Cell Res Ther 2018;9:243.
40. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23:1124–34.
41. Fradet V, Lessard L, Begin LR, et al. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460–4.
42. Kim SM, Lee SY, Cho JS, et al. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 2010;631:1–9.
43. Shaikh IA, Brown I, Schofield AC, et al. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 2008;68:1635–46.
44. Shrum CK, Defrancisco D, Meffert MK. Stimulated nuclear translocation of NF-kappaB and shuttling differentially depend on dynein and the dynactin complex. Proc Natl Acad Sci USA 2009;106:2647–52.
45. Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999;107:49–57.
46. Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008;76:939–46.
47. Sabour R, Harras MF, Al Kamaly OM, Altwaijry N. Discovery of novel 3-cyanopyridines as surviving modulators and apoptosis inducers. Molecules 2020;25:4892.